Ischemic/bleeding event after short dual-antiplatelet therapy in patients with high bleeding risk: Sub-analysis of the MODEL U-SES study.
| Autor: | Hioki H; Division of Cardiology, Teikyo University Hospital, 2-11-1 Kaga, Itabashi-ku, Tokyo 173-8605, Japan., Kozuma K; Division of Cardiology, Teikyo University Hospital, 2-11-1 Kaga, Itabashi-ku, Tokyo 173-8605, Japan. Electronic address: kozumak@med.teikyo-u.ac.jp., Kinoshita Y; Department of Cardiology, Toyohashi Heart Center, Toyohashi, Japan., Nanasato M; Department of Cardiology, Sakakibara Heart Institute, Fuchu, Japan., Ito Y; Department of Cardiology, Saiseikai Yokohamashi Tobu Hospital, Yokohama, Japan., Yamaguchi J; Department of Cardiology, Tokyo Women's Medical University, Tokyo, Japan., Shiode N; Department of Cardiology, Hiroshima City Hiroshima Citizens Hospital, Hiroshima, Japan., Hibi K; Division of Cardiology, Yokohama City University Medical Center, Yokohama, Japan., Tanabe K; Division of Cardiology, Mitsui Memorial Hospital, Tokyo, Japan., Ako J; Department of Cardiology, Kitazato University Hospital, Sagamihara, Japan., Morino Y; Department of Cardiology, Iwate Medical University Hospital, Morioka, Japan., Hirohata A; Department of Cardiology, Sakakibara Heart Institute of Okayama, Okayama, Japan., Sonoda S; Department of Cardiology, Hospital of the University of Occupational and Environmental Health, Kitakyushu, Japan., Nakagawa Y; Department of Cardiology, Shiga University of Medical Science Hospital, Otsu, Japan., Okada H; Department of Cardiology, Seirei Hamamatsu General Hospital, Shizuoka, Japan., Nakagami T; Department of Cardiology, Omihachiman Community Medical Center, Omihachiman, Japan., Takamisawa I; Department of Cardiology, Sakakibara Heart Institute, Fuchu, Japan., Ando K; Department of Cardiology, Kokura Memorial Hospital, Kitakyushu, Japan., Abe M; Department of Cardiology, National Hospital Organization Kyoto Medical Center, Kyoto, Japan., Ikari Y; Department of Cardiology, Tokai University Hospital, Isehara, Japan. |
|---|---|
| Jazyk: | angličtina |
| Zdroj: | Journal of cardiology [J Cardiol] 2021 Aug; Vol. 78 (2), pp. 107-113. Date of Electronic Publication: 2021 Apr 17. |
| DOI: | 10.1016/j.jjcc.2021.03.015 |
| Abstrakt: | Background: This analysis aimed to evaluate the clinical impact of high bleeding risk (HBR) on adverse events after percutaneous coronary intervention (PCI). Methods: We retrospectively analyzed 1695 patients in the MODEL U-SES study, which was a multicenter, open-label, prospective observational study evaluating safety of 3-month dual antiplatelet therapy (DAPT) after Ultimaster stent (Terumo Corporation, Tokyo, Japan) implantation at 65 sites in Japan. Patients were divided into 2 groups (HBR/Non-HBR) according to modified Academic Research Consortium-HBR criteria. Ischemic/thrombotic event (cardiovascular death, myocardial infarction, ischemic stroke, and stent thrombosis) and bleeding event (Bleeding Academic Research Consortium 3 or 5) at 1 year were evaluated. Results: Of 1695 patients, 840 patients were categorized as HBR and 855 patients were Non-HBR. One-year follow-up was completed in 95.3%. During 1-year follow-up, ischemic/thrombotic events were observed in 31 cases (1.8%) and bleeding events occurred in 21 cases (1.2%). Presence of HBR was significantly associated with higher incidence of ischemic/thrombotic events as compared to Non-HBR (adjusted hazard ratio, 0.16; 95% confidence interval, 0.05 to 0.50), whereas the incidence of bleeding events did not reach statistical significance between HBR and Non-HBR. In comparison of monotherapy after DAPT, P2Y Conclusion: In contemporary PCI practice, nearly half of patients had HBR and presence of HBR significantly increased risk of ischemic/thrombotic events. Both aspirin and P2Y (Copyright © 2021. Published by Elsevier Ltd.) |
| Databáze: | MEDLINE |
| Externí odkaz: |
|
Full Text from ScienceDirect